Antiviral therapy

Abstract

The present invention relates to combinations of compounds comprising HIV integrase inhibitors and other therapeutic agents. Such combinations are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC

What is claimed is: 
     
         1 . A combination comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, abacavir, or a pharmaceutically acceptable salt thereof, and lamivudine. 
     
     
         2 . A combination according to  claim 1  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         3 . A combination according to  claim 1  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         4 . A method of treatment of HIV infection comprising administering to a human, a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, abacavir, or a pharmaceutically acceptable salt thereof, and lamivudine. 
     
     
         5 . A method according to  claim 4  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         6 . A method according to  claim 4  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         7 . A pharmaceutical composition comprising a compound of formula (I) 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt thereof, abacavir, or a pharmaceutically acceptable salt thereof and lamivudine together with a pharmaceutically acceptable carrier therefor. 
     
     
         8 . A pharmaceutical composition according to  claim 7  wherein the pharmaceutically acceptable salt of abacavir is a hemisulfate salt. 
     
     
         9 . A pharmaceutical composition according to  claim 7  wherein the pharmaceutically acceptable salt of a compound of formula (I) is a sodium salt. 
     
     
         10 . A combination according to  claim 1  wherein the combination is administered simultaneously. 
     
     
         11 . A combination according to  claim 1  wherein the combination is administered sequentially. 
     
     
         12 . A method of treatment according to  claim 4  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine are administered simultaneously. 
     
     
         13 . A method of treatment according to  claim 4  wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine are administered sequentially. 
     
     
         14 . A patient pack comprising a compound of formula (I) according to  claim 1  or a pharmaceutically acceptable salt thereof, abacavir or a pharmaceutically acceptable salt thereof, and lamivudine.